ICU Medical (NASDAQ:ICUI - Get Free Report) is anticipated to announce its Q1 2025 earnings results after the market closes on Thursday, May 8th. Analysts expect ICU Medical to post earnings of $1.23 per share and revenue of $574.15 million for the quarter.
ICU Medical Trading Down 1.2 %
ICUI stock traded down $1.68 during midday trading on Tuesday, reaching $134.32. The stock had a trading volume of 297,522 shares, compared to its average volume of 274,375. The firm has a market cap of $3.31 billion, a price-to-earnings ratio of -29.39 and a beta of 0.87. ICU Medical has a twelve month low of $96.97 and a twelve month high of $196.26. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The business has a fifty day simple moving average of $140.93 and a two-hundred day simple moving average of $155.97.
Analyst Upgrades and Downgrades
ICUI has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a "hold" rating on shares of ICU Medical in a research note on Tuesday, April 8th. Raymond James set a $97.00 price objective on ICU Medical in a research note on Wednesday, March 12th. StockNews.com raised ICU Medical from a "hold" rating to a "buy" rating in a research note on Friday. Finally, KeyCorp lowered their price target on ICU Medical from $209.00 to $191.00 and set an "overweight" rating for the company in a research note on Monday, April 21st. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $162.67.
Get Our Latest Report on ICU Medical
About ICU Medical
(
Get Free Report)
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Further Reading
Before you consider ICU Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICU Medical wasn't on the list.
While ICU Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
